Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Roche gets U.S. approval for flu drug for children aged 5 and over

Published 08/12/2022, 01:23 AM
Updated 08/12/2022, 01:25 AM
© Reuters. FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.    REUTERS/Michael Buholzer/File Photo

ZURICH (Reuters) - Roche has received approval from the U.S. Food and Drugs Administration for its Xofluza drug to treat influenza in children aged five years and older, the drugmaker said on Friday.

The medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children who have shown symptoms for no more than 48 hours.

© Reuters. FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.    REUTERS/Michael Buholzer/File Photo

The FDA also approved Xofluza to prevent influenza in children aged five years and above following contact with an infected person.

The drug becomes the first single-dose oral influenza medicine approved in the United States for children in this age group, Roche said. Xofluza is already FDA-approved to treat influenza in people aged 12 and above.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.